K562/Anti-human CD3 & Anti-human CD16a Stable Cell Line Development Service

Co-expression analysis of anti-human CD3 and anti-human CD16a on K562/Anti-human CD3 & Anti-human CD16a Stable Cell Line by FACS.
Cell surface staining was performed on the K562/Anti-human CD3 & Anti-human CD16a Stable Cell Line and negative control cells, with the APC channel used to detect anti-human CD3 and the PE channel used to detect anti-human CD16a.

The K562/Anti-human CD3 & Anti-human CD16a stable cell line was employed as a target to assess the cytotoxic capacity of tumor-derived TILs.
TILs were co-cultured with either parental K562 cells or the K562/Anti-human CD3 & Anti-human CD16a stable cell line, and luciferase activity was quantified as a readout of target cell viability. Across multiple tumor types, TILs exhibited markedly augmented cytolytic activity against the engineered K562 line relative to parental K562 controls.

The K562/Anti-human CD3 & Anti-human CD16a stable cell line was utilized to evaluate NK cell-mediated cytotoxicity.
NK cells were co-cultured with either parental K562 cells or the K562/Anti-human CD3 & Anti-human CD16a stable cell line, followed by quantification of luciferase activity. Although NK cells displayed intrinsic cytotoxicity against K562 cells, lysis of the engineered line was substantially greater than that of the unmodified line at low effector-to-target (E:T) ratios.

The K562/Anti-human CD3 & Anti-human CD16a stable cell line was used to evaluate T cell-mediated cytotoxicity.
Donor-derived T cells were co-cultured with either parental K562 cells or the K562/Anti-human CD3 & Anti-human CD16a stable cell line, and luciferase activity was measured thereafter. T cells from multiple healthy donors demonstrated significantly enhanced killing efficacy against parental K562 cells.